Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 1997

View Archived Issues

Annual Report: CellPro

Annual Report: Cangene

ZymoGenetics/Novo Nordisk isolate anticlotting agent

EPO activators/agonists described by J&J and Affymax

X-ray contrast agents from Schering AG

Human Genome Sciences describes MCP-4 polypeptide

Anti-factor Xa compounds disclosed by RPR

Zeneca describes ET antagonists

Retinoid series for cancer

BASF prepares dolastatin derivatives

TK inhibitors disclosed by RCT

HMR synthesizes potent AChE inhibitor

Combination Remune/triple anti-HIV therapy trial begins

Neuraminidase inhibitor holds promise for flu

Approval anticipated for TMR using Heart Laser

Biopharmaceutics/ABS form advisory team to advance filings for anticancer drug

Alza/Alkermes stock purchase and development agreements

Clinical development of HIV immunotherapeutic advances

Gliatech's ADCON-L nears FDA approval

Nymox drug candidate for AD to enter phase I

Inex and Schering-Plough complete research collaboration

Positive phase I safety profile for Immunex's new product candidate

Dermik launches new acne medication

Popular Stories

23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema
BioWorld
Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...